Efficacy and Safety of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia Gravis

NCT06827587 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Myasthenia Gravis
Autoimmune Diseases
Neuromuscular Diseases

Interventions

DRUG: Efgartigimod + Telitacicept (1-week interval) group
DRUG: Efgartigimod + Telitacicept (2-week interval) group
DRUG: Telitacicept-only group

Sponsor

First Affiliated Hospital of Wenzhou Medical University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]